Equities Analysts Set Expectations for ENLV Q1 Earnings

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) – Equities researchers at HC Wainwright lowered their Q1 2026 earnings per share (EPS) estimates for shares of Enlivex Therapeutics in a research report issued on Tuesday, April 7th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($0.02) per share for the quarter, down from their prior forecast of ($0.01). HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Enlivex Therapeutics’ current full-year earnings is ($0.70) per share. HC Wainwright also issued estimates for Enlivex Therapeutics’ Q2 2026 earnings at ($0.02) EPS, Q3 2026 earnings at ($0.02) EPS, Q4 2026 earnings at ($0.02) EPS and FY2026 earnings at ($0.08) EPS.

A number of other equities analysts have also recently commented on the company. Wall Street Zen cut Enlivex Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enlivex Therapeutics in a research note on Monday, December 29th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Enlivex Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $16.50.

Enlivex Therapeutics Price Performance

Shares of Enlivex Therapeutics stock opened at $0.95 on Thursday. The business’s 50 day simple moving average is $1.07 and its two-hundred day simple moving average is $1.01. The stock has a market capitalization of $225.42 million, a P/E ratio of -1.73 and a beta of 1.68. Enlivex Therapeutics has a one year low of $0.66 and a one year high of $2.10.

Hedge Funds Weigh In On Enlivex Therapeutics

A number of large investors have recently bought and sold shares of ENLV. Virtu Financial LLC purchased a new position in Enlivex Therapeutics in the 4th quarter worth approximately $33,000. Invesco Ltd. purchased a new position in shares of Enlivex Therapeutics during the fourth quarter valued at approximately $43,000. XTX Topco Ltd increased its stake in shares of Enlivex Therapeutics by 44.8% during the fourth quarter. XTX Topco Ltd now owns 61,800 shares of the company’s stock valued at $43,000 after buying an additional 19,132 shares during the period. Jane Street Group LLC increased its stake in shares of Enlivex Therapeutics by 244.1% during the fourth quarter. Jane Street Group LLC now owns 74,082 shares of the company’s stock valued at $52,000 after buying an additional 52,553 shares during the period. Finally, Susquehanna International Group LLP purchased a new position in shares of Enlivex Therapeutics during the third quarter valued at approximately $57,000. 1.02% of the stock is owned by hedge funds and other institutional investors.

More Enlivex Therapeutics News

Here are the key news stories impacting Enlivex Therapeutics this week:

• Positive Sentiment: Ondo Finance launched ENLVon, a tokenized representation of Enlivex ordinary shares on Ondo’s Global Markets platform — this may improve liquidity, broaden investor access and make the stock more tradable internationally. Read More. Read More.
• Neutral Sentiment: HC Wainwright continues to rate ENLV a “Buy” with a $20.00 price target — that keeps a bullish long‑term analyst endorsement despite model changes. Read More.
• Negative Sentiment: HC Wainwright trimmed multiple near‑term EPS estimates: Q1–Q4 2026 and Q1–Q3/Q4 2027 quarterlies are modeled at ($0.02) each (up from prior ($0.01) in several quarters), and FY2026 EPS was cut to ($0.08) from ($0.05). The downward revisions signal weaker near‑term profitability expectations and could pressure the stock if operational/financial updates don’t show improvement. Read More.

About Enlivex Therapeutics

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.